Analyst Research

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC and Bristol-Myers Squibb announce U.S. FDA approval of Farxiga


Wednesday, 8 Jan 2014 05:06pm EST 

AstraZeneca PLC:Says the company and Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration (FDA) has approved Farxiga.AstraZeneca and Bristol-Myers Squibb are working in collaboration to develop and commercialize a versatile portfolio of treatment options for diabetes and related metabolic disorders that aim to provide treatment effects beyond glucose control. 

Company Quote

73.89
-0.59 -0.79%
28 Jul 2014